Loading...
XKRX
102460
Market cap152mUSD
Jun 16, Last price  
11,410.00KRW
1D
2.06%
1Q
-3.39%
Jan 2017
-48.01%
IPO
8.07%
Name

Reyon Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:102460 chart
P/E
50.41
P/S
1.41
EPS
226.34
Div Yield, %
—
Shrs. gr., 5y
1.16%
Rev. gr., 5y
2.42%
Revenues
148.30b
-1.83%
55,906,318,00072,932,904,00095,187,341,000120,827,191,000124,350,931,480114,334,848,060109,693,359,770112,112,066,710114,507,234,540121,847,219,920126,253,125,650122,990,417,380131,557,875,300130,034,153,190142,801,367,550154,038,839,260151,071,143,910148,299,673,630
Net income
4.15b
+15.85%
6,086,421,0008,065,547,00016,287,993,00019,981,933,00019,779,374,32016,990,558,94011,292,961,39011,593,285,51011,337,932,74010,701,369,00012,886,901,0001,342,892,9105,941,669,8003,844,427,1405,537,251,5307,433,682,1603,583,373,1204,151,240,200
CFO
-1.44b
L
8,049,026,0005,985,742,0008,683,539,00018,191,445,00013,238,641,08022,070,046,340-51,792,71015,102,444,1709,663,900,5809,471,438,00016,763,965,00011,449,210,060-12,183,515,7504,599,406,54011,684,528,3508,729,174,3708,645,127,290-1,435,814,430
Dividend
Dec 27, 2023150 KRW/sh

Profile

REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
URL
https://reyonpharm.co.kr/en/main/main.do
IPO date
Jun 10, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
148,299,674
-1.83%
151,071,144
-1.93%
154,038,839
7.87%
Cost of revenue
111,470,779
113,525,672
115,864,296
Unusual Expense (Income)
NOPBT
36,828,895
37,545,472
38,174,544
NOPBT Margin
24.83%
24.85%
24.78%
Operating Taxes
1,012,219
448,590
(539,767)
Tax Rate
2.75%
1.19%
NOPAT
35,816,676
37,096,882
38,714,310
Net income
4,151,240
15.85%
3,583,373
-51.80%
7,433,682
34.25%
Dividends
(2,751,149)
(2,737,914)
(4,563,189)
Dividend yield
1.18%
0.90%
1.19%
Proceeds from repurchase of equity
(3,830)
BB yield
0.00%
Debt
Debt current
90,659,960
102,265,540
24,754,331
Long-term debt
115,244,278
126,185,945
188,934,115
Deferred revenue
Other long-term liabilities
1,057,133
2,747,603
3,526,113
Net debt
179,684,345
182,994,506
171,428,067
Cash flow
Cash from operating activities
(1,435,814)
8,645,127
8,729,174
CAPEX
(16,011,730)
(28,869,949)
(63,133,217)
Cash from investing activities
(16,590,826)
(8,739,390)
(52,564,092)
Cash from financing activities
4,128,295
8,153,339
(6,767,466)
FCF
38,497,960
5,975,193
(26,173,810)
Balance
Cash
10,214,893
24,241,004
36,069,017
Long term investments
16,005,000
21,215,974
6,191,362
Excess cash
18,804,910
37,903,421
34,558,437
Stockholders' equity
216,690,380
214,748,543
221,739,437
Invested Capital
436,246,161
438,522,444
426,202,669
ROIC
8.19%
8.58%
9.72%
ROCE
8.09%
7.88%
8.29%
EV
Common stock shares outstanding
18,216
18,341
17,753
Price
12,840.00
-22.37%
16,540.00
-23.60%
21,650.00
-39.10%
Market cap
233,891,488
-22.90%
303,359,991
-21.07%
384,347,189
-38.98%
EV
413,575,833
486,354,497
556,025,256
EBITDA
43,172,493
42,327,706
42,708,054
EV/EBITDA
9.58
11.49
13.02
Interest
1,252,962
193,815
122,198
Interest/NOPBT
3.40%
0.52%
0.32%